CRDF Cardiff Oncology: Earnings per share for the last 12 months

Cardiff Oncology Corp (CRDF) - corporate logo

The financial price visualization for Cardiff Oncology, Inc. (CRDF) demonstrates EPS dynamics, where the current figure is 32.70. Cardiff Oncology, Inc. (CRDF) develops innovative inhibitors to combat tumor resistance while avoiding price wars. The business relies on the success of kinase drugs and their synergy with chemotherapy to extend patient survival. High-paid oncology experts lead these developments, utilizing access to cutting-edge laboratory facilities to achieve scientific breakthroughs.

Cardiff Oncology Corp (CRDF) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/18/2026

CRDF (Cardiff Oncology Corp): analytical breakdowns and indicator data

- price and consensus price forecast:
Fundamental company valuation:CRDF Cardiff Oncology, Inc.
Flagship merchandise of Cardiff Oncology Inc.

The automation of cancer inhibitor design via AI and robotics at Cardiff Oncology, Inc. (CRDF) directly impacts the annual percentage change in earnings per share (TTM). This indicator captures the net income trend over the last 12 months relative to the same period last year. The calculation is based on a comparison of rolling annual EPS totals, which eliminates quarterly volatility. Growth in this metric confirms the efficiency of R&D digitalization, while a decline signals a risk of compression in investment multiples.

Direct competitors

Net earnings per one share for the last twelve months Incyte Corp|HCM: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NUVB|DAWN (dayonebio.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months monopartx.com (MNPR)|Earnings per share for the last twelve months Inhibrx Corp (INBX)|IMAB - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Fennec Pharmaceuticals Inc FENC|Heron Therapeutics - Earnings per share for the last twelve months|NVCT - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months coherus.com|CRBP: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BeyondSpring Pharma BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals Inc.)|CLRB (Cellectar Biosciences, Inc.) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (Can-Fite BioPharma Ltd.)|Aprea Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (kaziatherapeutics.com)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana Corp (NCNA)|Earnings per share for the last twelve months Chimerix|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Corporation (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Therapeutics, Inc.) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months